Where Chips
Meet Cells
Taiwan makes the silicon the world’s AI runs on. Now it wants the same edge in medicine — fusing semiconductors, AI and one of the planet’s largest genomic cohorts into a precision-health advantage. The question is whether compute can become cures.
From compute to cures — the lens of the report
Taiwan has the inputs; the test is the last, hardest step. Tap a stage to see where the island stands today.
Seven beats, one question
A ~3,200-word analysis, told in seven sections. Browse the argument, then download the full report for the sourcing and detail.
Where the resources concentrate
Four overlapping bets, each leaning on the same chips-and-data foundation. Tap each to expand.
| Bet | Maturity in Taiwan |
Compute & data fit |
Home-grown ownership |
|---|
The inputs, by the numbers
Taiwan’s biotech, mapped
The asset base by cluster — tap a marker or a row to explore.
From inputs to approved drugs
A handful of genuine global innovators — and, newest of all, the chip majors moving into health.
What to watch · 2026–2029
- Clinically deployed precision-medicine tools from the TPMI genomic cohort — not just papers.
- The ‘Healthy Taiwan’ AI build-out moving from hospital operations into drug discovery.
- Diagnostics and biomedical-chip exports as a near-term, chip-native revenue line.
- New homegrown approvals — PharmaEssentia’s label expansions and the next firm to follow TaiMed through the FDA.
- Cross-strait risk staying a manageable discount rather than a binding constraint on capital.
Get the full report free
- The full chips-meet-cells analysis, sourced throughout
- The TPMI cohort, science-budget and chip-share data visuals
- A Taiwan biotech cluster map and the four-bets matrix
- Profiles of PharmaEssentia, TaiMed and the Foxconn×NVIDIA crossover
Your report is downloading
Thanks — enjoy the read. If the download didn’t start automatically, use the button below.
Download the PDF ↓